TCGA-63-7022-01A-11R-1949-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.630
- ANGIOGENESIS+0.510
- HEDGEHOG_SIGNALING+0.510
- ALLOGRAFT_REJECTION+0.460
- IL6_JAK_STAT3_SIGNALING+0.430
- APICAL_SURFACE+0.410
- INFLAMMATORY_RESPONSE+0.370
- COMPLEMENT+0.360
- MYOGENESIS+0.360
- WNT_BETA_CATENIN_SIGNALING+0.360
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.520
- MYC_TARGETS_V1-0.490
- E2F_TARGETS-0.460
- MYC_TARGETS_V2-0.430
- G2M_CHECKPOINT-0.330
- FATTY_ACID_METABOLISM-0.320
- MTORC1_SIGNALING-0.300
- PROTEIN_SECRETION-0.300
- ADIPOGENESIS-0.270
- CHOLESTEROL_HOMEOSTASIS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-78-8648-01A-11R-2403-07 | — | cohortMD2 | 0.916 |
| 2 | f22cfa82-a346-4fed-bc81-21a29bf990ee | — | — | 0.916 |
| 3 | 21196229-e39e-4846-be58-a1055b3ae50e | — | — | 0.916 |
| 4 | 4925248f-21e2-476e-937c-02e0a748c77b | — | — | 0.908 |
| 5 | TCGA-50-8459-01A-11R-2326-07 | — | cohortMD2 | 0.906 |
| 6 | SRR23303731 | — | — | 0.902 |
| 7 | c277dab0-361f-4aa6-96b1-522a6e556ae1 | — | — | 0.902 |
| 8 | TCGA-XF-AAME-01A-12R-A42T-07 | — | — | 0.901 |
| 9 | ec054d40-e5b8-496a-8c99-5e7f88f2cf37 | — | — | 0.898 |
| 10 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.898 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.630 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.510 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.510 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.460 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.410 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.360 | Inavolisib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.340 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.330 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.310 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.300 | Idelalisib | — uncovered |
| HYPOXIA | 0.270 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.250 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.150 | Inavolisib | — uncovered |
| APOPTOSIS | 0.120 | Idelalisib | — uncovered |